Similar Papers

Paper Title
Journal
Date
Author
Data from A Risk Variant in an miR-125b Binding Site in <i>BMPR1B</i> Is Associated with Breast Cancer Pathogenesis
Al B Benson ... Theodore G Krontiris
-
Al B Benson, et. al.Al B Benson ... Theodore G Krontiris
30 Mar 2023
A Risk Variant in an miR-125b Binding Site in BMPR1B Is Associated with Breast Cancer Pathogenesis
PåL Sætrom ... John M Kirkwood
Cancer Research | VOL. 69
PåL Sætrom, et. al.PåL Sætrom ... John M Kirkwood
14 Sep 2009
Data from A Risk Variant in an miR-125b Binding Site in <i>BMPR1B</i> Is Associated with Breast Cancer Pathogenesis
Al B Benson ... Theodore G Krontiris
-
Al B Benson, et. al.Al B Benson ... Theodore G Krontiris
30 Mar 2023
Abstract 246: An integrative genetic epidemiologic approach to identify susceptibility genes for post-menopausal breast cancer
Roxana Moslehi ... Amiran Dzutsev
Cancer Research | VOL. 78
Roxana Moslehi, et. al.Roxana Moslehi ... Amiran Dzutsev
01 Jul 2018
View more papers

More From: Cancer Biology & Therapy

Paper Title
Journal
Date
Author
The mitochondria as an emerging target of self-renewal in T-cell acute lymphoblastic leukemia
Majd A Al-Hamaly ... Jessica S Blackburn
Cancer Biology & Therapy | VOL. 26
Majd A Al-Hamaly, et. al.Majd A Al-Hamaly ... Jessica S Blackburn
04 Feb 2025
Caspase 3-specific cleavage of ubiquitin-specific peptidase 48 enhances drug-induced apoptosis in AML
Zhanglin Zhang ... Guangyao Kong
Cancer Biology & Therapy | VOL. 26
Zhanglin Zhang, et. al.Zhanglin Zhang ... Guangyao Kong
29 Jan 2025
Targeting the IKZF1/BCL-2 axis as a novel therapeutic strategy for treating acute T-cell lymphoblastic leukemia
Juan Li ... Jun Li
Cancer Biology & Therapy | VOL. 26
Juan Li, et. al.Juan Li ... Jun Li
25 Jan 2025
NVP-2, in combination with Orlistat, represents a promising therapeutic strategy for acute myeloid leukemia
Qing Zhu ... Peifang Xiao
Cancer Biology & Therapy | VOL. 26
Qing Zhu, et. al.Qing Zhu ... Peifang Xiao
12 Jan 2025
View more papers

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.